Plasma GABA predicts acute response to divalproex in mania

Frederick Petty, A. John Rush, John M. Davis, Joseph R. Calabrese, Susan E. Kimmel, Gerald L. Kramer, Joyce G. Small, Marvin J. Miller, Alan E. Swann, Paul J. Orsulak, Molly E. Blake, Charles L. Bowden

Research output: Contribution to journalArticlepeer-review

49 Scopus citations


Bipolar I, manic phase inpatients were treated with divalproex sodium, lithium, or placebo in a previously reported parallel group multicenter, double-blind, randomized, controlled acute phase treatment trial, Plasma concentrations of gamma aminobutyric acid (GABA) were measured before and after treatment. Higher pretreatment plasma GABA levels were significantly (p = .04) related to a better clinical response to divalproex (n = 19). Pretreatment plasma GABA levels did not correlate with response to either lithium (n = 13) or placebo (n = 31). Following treatment with divalproex sodium, plasma GABA levels decreased significantly (p <.05), compared to placebo. Pretreatment plasma GABA levels were not related to overall severity of manic symptoms. Plasma GABA may predict response to pharmacologic agents acting on the GABA system.

Original languageEnglish (US)
Pages (from-to)278-284
Number of pages7
JournalBiological Psychiatry
Issue number4
StatePublished - Feb 15 1996


  • Bipolar disorder
  • Divalproex
  • GABA
  • Lithium
  • Mania
  • Response prediction
  • Valproic acid

ASJC Scopus subject areas

  • Biological Psychiatry


Dive into the research topics of 'Plasma GABA predicts acute response to divalproex in mania'. Together they form a unique fingerprint.

Cite this